{
    "clinical_study": {
        "@rank": "48727", 
        "acronym": "SELF CARE", 
        "arm_group": [
            {
                "arm_group_label": "A (BGStar)", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly."
            }, 
            {
                "arm_group_label": "B (traditional approach)", 
                "arm_group_type": "Active Comparator", 
                "description": "Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter."
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate the superiority of a chronic care model (SINERGIA model) supported by the\n      Self Monitoring of Blood Glucose with BGStar over usual care in improving glycemic control\n      at 12 months in patients with type 2 diabetes not treated with insulin."
        }, 
        "brief_title": "Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The planned study duration is 36 months (9 quarters). The estimated duration of\n      screening/enrollment will be 12 months, followed by the 12-month experimental phase, plus\n      the 12-month follow-up in the observational phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females\n\n          -  Age \u2265 45 years\n\n          -  Type 2 diabetes\n\n          -  First access at the diabetes clinic\n\n          -  Any diabetes duration\n\n          -  HbA1c >7.0 and \u2264 9.0%\n\n          -  Already treated with any oral antidiabetic agent (OAD) or requiring the initiation of\n             therapy with OAD\n\n          -  Patients not using SMBG or using SMBG with a frequency \u22641 test/week\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n        Treatment with insulin or need to start insulin regimens or continuous sub-cutaneous\n        insulin infusion at the first access; Refusal or inability to give informed consent to\n        participate in the study;\n\n        Conditions / situations such as:\n\n          -  Patients with short life expectancy;\n\n          -  Patients with conditions/concomitant diseases making them non evaluable for the\n             primary efficacy endpoint according to physician's judgment;\n\n          -  Requirement for concomitant treatment that could bias primary evaluation (i.e.\n             corticosteroid treatment);\n\n          -  Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist,\n             study coordinator, other study site staff or relative of study site staff thus\n             considered directly involved in the conduct of the study;\n\n          -  Current addition/abuse of alcohol or drugs;\n\n          -  Patients with any mental condition rendering them unable to understand the nature,\n             scope, and possible consequences of the study;\n\n          -  Pregnant or breast-feeding women;\n\n          -  Patients living too far from investigational center or other conditions reducing the\n             adherence to the protocol; Subjects unlikely or unable  to comply with the Protocol\n             requirements (e.g. illiterate, uncooperative, unable to return for follow-up visit,\n             unable to use BGStar unlikely to complete the study)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "238", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082028", 
            "org_study_id": "BGSTA_L_05978"
        }, 
        "intervention": [
            {
                "arm_group_label": "A (BGStar)", 
                "intervention_name": "BGStar", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "B (traditional approach)", 
                "intervention_name": "glucose meter", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "Randomized Clinical Trial on the Efficacy of Self-Monitoring Blood Glucose in the Context of a Chronic Care Model for Type 2 Diabetes Patients Treated With Oral Agents Only", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Science & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c levels from baseline", 
            "safety_issue": "No", 
            "time_frame": "baseline to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with HbA1c \u22647.0%", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "Variation in body weight from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "Variation in  waist circumference from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "Variation in blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "Variation in lipid profile from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "Quality of life: SF12 (Health Survey) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "ADDQOL (Audit of Diabetes-Dependent Quality of Life)", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "DTSQ (Diabetes Treatment Satisfaction Questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "ABIM-14 (American Board of Internal Medicine satisfaction questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "PDM (Patient involvement in the Decision Making process) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "PHCO (Patient Health Care Orientation) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }, 
            {
                "measure": "Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "at 12 months and 24 months"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}